<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Urokinase</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00013</strong>&#160; (BIOD00030, BTD00030)</td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved, investigational, withdrawn</td></tr><tr><th>Description</th><td><p>Low molecular weight form of human urokinase, that consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Recombinant urokinase plasminogen activator</p></td></tr><tr><th>Protein structure</th><td><a href="/system/protein_structures/full/DB00013.png?1266600383"><img alt="Db00013" src="/system/protein_structures/thumb/DB00013.png?1266600383"></a></td></tr><tr><th>Protein chemical formula</th><td>C<sub>1376</sub>H<sub>2145</sub>N<sub>383</sub>O<sub>406</sub>S<sub>18</sub></td></tr><tr><th>Protein average weight</th><td>31126.5000</td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;DB00013 sequence
KPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMS
PCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHND
IALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMT
VVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVS
WGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB00013/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>U-plasminogen activator</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>uPA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Urokinase-type plasminogen activator precursor</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Abbokinase</td><td>Abbott Laboratories</td></tr><tr><td>Kinlytic</td><td>Microbix Biosystems Inc.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/thrombolytic-agents">Thrombolytic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>9039-53-6</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.</td></tr><tr><th>Pharmacodynamics</th><td>Urokinase is used for the treatment of pulmonary embolisms. The low molecular weight form of human urokinase consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Urokinase is an enzyme (protein) produced by the kidney, and found in the urine. There are two forms of urokinase which differ in molecular weight but have similar clinical effects. Urokinase is the low molecular weight form. Urokinase acts on the endogenous fibrinolytic system. It converts plasminogen to the enzyme plasmin. Plasmin degrades fibrin clots as well as fibrinogen and some other plasma proteins.</td></tr><tr><th>Mechanism of action</th><td>Urokinase acts on the endogenous fibrinolytic system. It cleaves the Arg-Val bond in plasminogen to produce active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Proteolysis</p></td></tr><tr><th>Route of elimination</th><td>Urokinase administered by intravenous infusion is rapidly cleared by the liver. Small fractions of the administered dose are excreted in bile and urine</td></tr><tr><th>Half life</th><td>12 minutes. Small fractions of the administered dose are excreted in bile and urine</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Urokinase Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Microbix biosystems inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.imarx.com">ImaRx Therapeutics</a></li>
<li><a href="http://www.microbix.com">Microbix Biosystems Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06692">Aprotinin</a></td><td>Aprotonin may antagonize the effect of Urokinase. Monitor for decreased effects of Urokinase.</td></tr><tr><td><a href="/drugs/DB00055">Drotrecogin alfa</a></td><td>Increased risk of bleeding. </td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Increased risk of bleeding. </td></tr><tr><td><a href="/drugs/DB01404">Ginseng</a></td><td>Increased risk of bleeding. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>